KRAS and neoplasm: Combination treatment with KRAS G12C inhibitor plus anti-PD-1 blockade cured the majority of mice in the CT-26 syngeneic colorectal cancer subcutaneous model (12, 55) and in a T-cell inflamed, TLS containing KRAS-mutant orthotopic LUAD model (31, 54), and also caused sustained tumor regression in an orthotopic PDAC model (bioRxiv.